The global cancer imaging systems market is projected to be worth USD 12.24 Billion by 2027, according to a current analysis by Emergen Research. The cancer imaging systems market is observing high demand attributed to the increasing incidence of cancer. Cancer significantly impacts the societal and economic growth in the US and worldwide and is a major contributor to the cost burden of disease. It has been anticipated that 1,806,590 new cancer cases are likely to be diagnosed in the US in 2020, and 606,520 deaths will occur owing to the disease.
How will this Report Benefit you?
An Emergen Research report of 250 pages contains 194 tables, 189 charts and graphics, and anyone who needs a comprehensive analysis of the global Cancer Imaging Systems market, as well as commercial, in-depth analyses of the individual segments, will find the study useful. Our recent study allows you to assess the entire regional and global market for Cancer Imaging Systems. In order to increase market share, obtain financial analysis of each segment and the whole market. Look at how you can utilize the current and potential revenue-generating opportunities available in this sector. We believe that there are significant prospects for energy storage technology in this industry due to the rapid expansion of the technology. In addition to helping you build growth strategies, improve competitor analysis, and increase business productivity, the research will also assist you in making better strategic decisions.
The leading market contenders listed in the report are:
GE Healthcare, Hitachi Medical, Becton, Dickinson, and Company, Thermo Fisher Scientific Inc., CR Bard Inc., Agilent Technologies, Abbott, Illumina Inc., Roche,, Philips Healthcare
Market Segmentations of the Cancer Imaging Systems Market
Segments Covered in this report are:
-
Imaging Systems Outlook (Revenue, USD Billion; 2017-2027)
- Mammography
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Ultrasound
- Positron Emission Tomography (PET)
- Others
-
Application Outlook (Revenue, USD Billion; 2017-2027)
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Melanoma
- Others
-
End-Users Outlook (Revenue, USD Billion; 2017-2027)
- Hospitals & Clinics
- Diagnostic Centers
- Others
